(ALMKS) Making Science S.A. - Ratings and Ratios
Exchange: PA •
Country: Spain •
Currency: EUR •
Type: Common Stock •
ISIN: (N/A)
Advertising, Analytics, Software, eCommerce, Cloud, Data
ALMKS EPS (Earnings per Share)
ALMKS Revenue
Description: ALMKS Making Science S.A.
from quarterly Tax Provision
ALMKS Stock Overview
| Market Cap in USD | 96m |
| Sub-Industry | Advertising |
| IPO / Inception |
ALMKS Stock Ratings
| Growth Rating | -30.9% |
| Fundamental | - |
| Dividend Rating | - |
| Return 12m vs S&P 500 | -4.02% |
| Analyst Rating | - |
ALMKS Dividends
Currently no dividends paidALMKS Growth Ratios
| Growth Correlation 3m | 69% |
| Growth Correlation 12m | 38% |
| Growth Correlation 5y | -96% |
| CAGR 5y | -19.78% |
| CAGR/Max DD 5y | -0.26 |
| Sharpe Ratio 12m | -0.27 |
| Alpha | 8.86 |
| Beta | -0.062 |
| Volatility | 6.47% |
| Current Volume | 0k |
| Average Volume 20d | 0k |
| Stop Loss | 8.5 (-7.1%) |
| Signal | 0.22 |
What is the price of ALMKS shares?
As of September 01, 2025, the stock is trading at EUR 9.15 with a total of 1 shares traded.
Over the past week, the price has changed by +0.00%, over one month by +1.10%, over three months by +1.10% and over the past year by +12.27%.
Over the past week, the price has changed by +0.00%, over one month by +1.10%, over three months by +1.10% and over the past year by +12.27%.
Is Making Science S.A. a good stock to buy?
Probably not. Based on ValueRay´s Analyses, Making Science S.A. (PA:ALMKS) is currently (September 2025)
not a good stock to buy. It has a ValueRay Growth Rating of -30.92 and therefor a somwhat technical negative rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ALMKS is around 7.34 EUR . This means that ALMKS is currently overvalued and has a potential downside of -19.78%.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of ALMKS is around 7.34 EUR . This means that ALMKS is currently overvalued and has a potential downside of -19.78%.
Is ALMKS a buy, sell or hold?
Making Science S.A. has no consensus analysts rating.
What are the forecasts/targets for the ALMKS price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 8 | -12.8% |
ALMKS Fundamental Data Overview
Market Cap USD = 96.1m (82.5m EUR * 1.1648 EUR.USD)
Market Cap EUR = 82.5m (82.5m EUR * 1.0 EUR.EUR)
CCE Cash And Equivalents = unknown
Revenue TTM is 0, using Net Income TTM 0.0 + Cost of Revenue 0.0 = 0.0 EUR
P/S = 0.3015
P/B = 3.1512
Beta = 1.113
Revenue TTM = 0.0 EUR
EBIT TTM = 0.0 EUR
EBITDA TTM = 0.0 EUR
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 82.5m EUR (82.5m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
FCF Yield = none (FCF TTM 0.0 / Enterprise Value 82.5m)
FCF Margin = unknown (Revenue TTM is 0)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 82.5m / Book Value Of Equity 0.0)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt none)
Taxrate = unknown
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown Debt (none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = none (Debt none / FCF TTM 0.0)
Total Stockholder Equity = unknown
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity none)
RoCE = unknown (Ebit 0.0 / (Equity none + L.T.Debt none))
RoIC = unknown (NOPAT none, Invested Capital 0.0, Ebit 0.0)
WACC = unknown (E(82.5m)/V(0.0) * Re(5.79%)) + (D(none)/V(0.0) * Rd(0.0%) * (1-Tc(none)))
Discount Rate = 5.79% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow 0.0)
EPS Correlation: -38.87 | EPS CAGR: 0.0%
EPS Growth-of-Growth: 0.00
Market Cap EUR = 82.5m (82.5m EUR * 1.0 EUR.EUR)
CCE Cash And Equivalents = unknown
Revenue TTM is 0, using Net Income TTM 0.0 + Cost of Revenue 0.0 = 0.0 EUR
P/S = 0.3015
P/B = 3.1512
Beta = 1.113
Revenue TTM = 0.0 EUR
EBIT TTM = 0.0 EUR
EBITDA TTM = 0.0 EUR
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 82.5m EUR (82.5m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
FCF Yield = none (FCF TTM 0.0 / Enterprise Value 82.5m)
FCF Margin = unknown (Revenue TTM is 0)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 82.5m / Book Value Of Equity 0.0)
Interest Expense / Debt = 0.0% (Interest Expense 0.0 / Debt none)
Taxrate = unknown
NOPAT = unknown (EBIT/Op.Income or Taxrate missing)
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown Debt (none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = none (Debt none / FCF TTM 0.0)
Total Stockholder Equity = unknown
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity none)
RoCE = unknown (Ebit 0.0 / (Equity none + L.T.Debt none))
RoIC = unknown (NOPAT none, Invested Capital 0.0, Ebit 0.0)
WACC = unknown (E(82.5m)/V(0.0) * Re(5.79%)) + (D(none)/V(0.0) * Rd(0.0%) * (1-Tc(none)))
Discount Rate = 5.79% (= CAPM, Blume Beta Adj.) -> floored to rf + ERP 8.05%
Fair Price DCF = unknown (Cash Flow 0.0)
EPS Correlation: -38.87 | EPS CAGR: 0.0%
EPS Growth-of-Growth: 0.00